20 August 2021 - Pfizer announced today that the European Commission has approved Xeljanz (tofacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis in patients two years of age and older who have responded inadequately to previous therapy with disease modifying anti-rheumatic drugs. 

Two formulations were approved, a tablet and a new oral solution (weight-based dosing).

Read Pfizer press release